Crypt dysplasia with surface maturation: A clinical, pathologic, and molecular study of a Barrett's esophagus cohort

American Journal of Surgical Pathology

Volumn 30, Issue 4, 2006, Pages 423-435

  Lomo, Leslie C ^a   Blount, Patricia L ^b,c   Sanchez, Carissa A ^b   Li, X ^b   Galipeau, Patricia C ^b   Cowan, David S ^b   Ayub, Kamran ^c,d   Rabinovitch, Peter S ^c   Reid, Brian J ^b,c   Odze, Robert D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

Aneuploidy; Barrett's esophagus; Dysplasia; Loss of heterozygosity; p53; Proliferation

Indexed keywords

KI 67 ANTIGEN; MOLECULAR MARKER; PROTEIN P53; DNA; TUMOR MARKER;

ADULT; ANEUPLOIDY; ARTICLE; BARRETT ESOPHAGUS; CELL PROLIFERATION; COHORT ANALYSIS; CRYPT CELL; DYSPLASIA; ESOPHAGUS BIOPSY; FEMALE; HETEROZYGOSITY LOSS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ADENOCARCINOMA; AGED; CHROMOSOME 17; CHROMOSOME 9; ESOPHAGUS TUMOR; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PRECANCER; PREVALENCE; PROSPECTIVE STUDY; RISK FACTOR; STOMACH MUCOSA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 9; COHORT STUDIES; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; GASTRIC MUCOSA; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33646682387     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-200604000-00001     Document Type: Article

References (32)

1. Barrett MT, Reid BJ, Joslyn G. Genotypic analysis of multiple loci in somatic cells by whole genome amplification. Nucleic Acids Res. 1995;23:3488-3492.
2. Barrett MT, Galipeau PC, Sanchez CA, et al. Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms. Oncogene. 1996;12:1873-1878.
3. Conio M, Blanchi S, Lapertosa G, et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: prospective study. Am J Gastroenterol. 2003;98:1931-1939.
4. Drewitz DJ, Sampliner RE, Garewall HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol. 1997;92:212-215.
5. Galipeau PC, Prevo LJ, Sanchez CA, et al. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst. 1999;91:2085-2095.
6. Haggitt RC, Tryzelaar J, Ellis H, et al. Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Am J Clin Pathol. 1978;90:1-5.
7. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol. 1994;25:982-993.
8. Jass JR, Whitehall VL, Young J, et al. Emerging concepts in colorectal neoplasia. Gastroenterology. 2002;123:862-876.
9. Kilgare SP, Sigel JE, Goldblum JR. Hyperplastic-like mucosal change in Crohn's disease: an unusual form of dysplasia? Mod Pathol. 2000;13:797-801.
10. Levi G, Harpaz N. Low-grade tubuloglandular adenocarcinoma associated with inflammatory bowel disease: a study of 21 cases. Mod Pathol. 2005;18:110A.
11. Levine DS, Reid BJ. Endoscopic biopsy technique for acquiring larger mucosal samples. Gastrointest Endosc. 1991;37:332-337.
12. Levine DS. Management of dysplasia in the columnar-lined esophagus. Gastroenterol Clin North Am. 1997;26:613-634.
13. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's esophagus. Gut. 1991;32:1141-1146.
14. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett's esophagus: a reaffirmation. Hum Pathol. 2001;32:368-378.
15. Montgomery E, Goldblum JR, Greenson JK, et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett's esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol. 2001;32:379-388.
16. Ofman JJ, Lewin K, Ramers C, et al. The economic impact of the diagnosis of dysplasia in Barrett's esophagus. Am J Gastroenterol. 2000;95:2946-2952.
17. Paulson TG, Galipeau PC, Reid BJ. Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR. Genome Res. 1999;9:482-491.
18. Rabinovitch PS, Longton G, Blount PL, et al. Predictors of progression Barrett's esophagus: III. Baseline flow cytometric variables. Am J Gastroenterol. 2001;96:3071-3083.
19. Rabinovitch PS. DNA Histogram Analysis, Cell Growth and Division. 2nd ed. Oxford: Oxford University Press; 1994.
20. Reid BJ, Blount PL, Rubin CE, et al. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology. 1992;102:1212-1219.
21. Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol. 1988;19:166-178.
22. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol. 2000;95:1669-1676.
23. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus: II. Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol. 2001;96:2839-2848.
24. Reid BJ, Sanchez CA, Blount PL, et al. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology. 1993;105:119-129.
25. Rubio CA. Colorectal adenomas: time for reappraisal. Pathol Res Pract. 2002;198:615-620.
26. Rubio CA, Liu FS, Zhao HZ. Histological classification of intraepithelial neoplasias and microinvasive squamous carcinoma of the esophagus. Am J Surg Pathol. 1989;13:685-690.
27. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology. 2001;120:1607-1619.
28. Teodori L, Gohde W, Persiani M, et al. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a cohort of patients. Cytometry. 1998;34:257-263.
29. Wang G-Q, Abnet CC, Shen Q, et al. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. Gut. 2005;54:187-192.
30. Weston AP, Banerjee S, Sharma P, et al. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol. 2001;96:1355-1362.
31. Weston AP, Sharma P, Topalovski M, et al. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol. 2000;95:1887-1893.
32. Weston AP, Krmpotich PT, Cherian R, et al. Prospective long-term endoscopic and histologic follow-up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus. Am J Gastroenterol. 1997;92:407-413.